Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesDermatologyCigna topical non‑retinoid acne Coverage Update | …
    Ask Trek AI about this page
    CurrentCignaPolicy IP0166

    Topical Acne-Non-Retinoid Products

    Customize your policy alerts

    Sign up for Cigna Policy IP0166 alerts

    Get alerted when Policy IP0166 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and coverage criteria for topical non‑retinoid acne products (e.g., clindamycin, minocycline, combination benzoyl peroxide products) for Cigna‑administered health plans.

    Policy Summary
    PayerCigna
    PolicyTopical Acne-Non-Retinoid Products
    Policy CodePolicy IP0166
    Change TypeRemoved dapsone criteriapreference table revised
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review Date
    Key ActionObtain prior authorization and document required prior trials, contraindications, or intolerance per product-specific criteria before coverage will be approved.
    SourceLink
    POLICY UPDATE CHANGES

    Removed Dapsone products (Aczone) medical necessity criteria from this policy.

    Employer Preferred Product table: Removed Onexton preferred product requirements.

    No criteria changes noted for recent reviews leading to effective date 08/15/2026.

    12 monthsinitial authorization duration
    12 monthsreauthorization duration
    Multiplecovered product list

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Removed
    Aczone (dapsone) criteria

    Coverage Criteria for Topical Non‑Retinoid Acne Products

    Clindamycin-containing products (Clindagel) — Employer Plans

    Covered when ALL of the following are met:

    Clindagel medical necessity: 1) Trial of clindamycin phosphate 1% topical gel (the bioequivalent generic product) AND unable to take the bioequivalent generic due to a formulation difference in the inactive ingredient(s) resulting in a significant allergy or serious adverse reaction; 2) Failure, contraindication, or intolerance to BOTH: A) dapsone 5% topical gel; B) erythromycin 2% topical gel.

    Employer plan specific wording.

    Amzeeq (minocycline 4% foam) — Employer Plans

    Covered when ALL of the following are met:

    Amzeeq (minocycline 4% foam) medical necessity: Failure, contraindication, or intolerance to BOTH of the following: 1) ONE topical clindamycin-containing product (for example, clindamycin topical antibiotic [various formulations], clindamycin/benzoyl peroxide 1%/5% gel, clindamycin/tretinoin 1.2%/0.025% gel); 2) ONE topical erythromycin-containing product (for example, erythromycin topical antibiotics [various formulations], erythromycin/benzoyl peroxide 3%/5% gel).

    Employer plan specific wording.

    Combination clindamycin/benzoyl peroxide products (Acanya, BenzaClin, clindamycin/benzoyl formulations, Neuac, Onexton) — Employer Plans

    Covered when specified combinations of prior trials or failures are documented:

    Acanya medical necessity: 1) Trial of clindamycin 1.2%/benzoyl peroxide 2.5% topical gel (the bioequivalent generic product) AND unable to take due to a formulation difference in the inactive ingredient(s) resulting in a significant allergy or serious adverse reaction; 2) Failure, contraindication, or intolerance to BOTH specified alternatives.

    Employer plan wording.

    BenzaClin medical necessity: 1) Trial of clindamycin 1%/benzoyl peroxide 5% topical gel (the bioequivalent generic product) AND unable to take due to a formulation difference in the inactive ingredient(s) resulting in a significant allergy or serious adverse reaction; 2) Failure, contraindication, or intolerance to BOTH: A) topical benzoyl peroxide (4% or 8% gel) with topical clindamycin (1% gel) used concurrently; B) benzoyl peroxide/erythromycin 5%/3% topical gel.

    Employer plan wording.

    Clindamycin phosphate/benzoyl peroxide 1.2%/3.75% gel medical necessity: Considered medically necessary when there is documentation of failure, contraindication, or intolerance to ONE of the following: 1) clindamycin 5%/benzoyl peroxide 1.2% topical gel; 2) clindamycin 1%/benzoyl peroxide 5% topical gel.

    Clindamycin/benzoyl peroxide 1.2%/3.75% gel — Individual and Family Plans

    Covered when ONE of the following alternative trials is documented:

    Individual and Family plan clindamycin/benzoyl peroxide 1.2%/3.75% gel: Documentation of failure, contraindication, or intolerance to ONE of: 1) clindamycin 5%/benzoyl peroxide 1.2% topical gel; 2) clindamycin 1%/benzoyl peroxide 5% topical gel.1 of 2

    Individual and Family plan wording.

    The medical necessity criteria for dapsone topical products (Aczone) have been removed from this policy. This change is documented in the Revision Details as “Removed Dapsone products (Aczone) medical necessity criteria from this policy,” with the removal recorded 09/19/2024 and an effective date of 01/01/2025. Providers should no longer reference this policy for coverage criteria specific to Aczone.

    Claims for services that are billed for conditions or diagnoses not covered under this Coverage Policy will be denied as not covered. When submitting claims, providers must use the most appropriate diagnosis and procedure codes as of the date of submission; claims submitted without covered code(s) under this policy are subject to denial.

    Provider Actions, Prior Authorization and Documentation Requirements

    Prior Authorization

    Obtain prior authorization when coverage criteria are met for branded topical non‑retinoids

    Prior authorization is required when coverage is available and the medical necessity criteria in this policy are met for branded topical non‑retinoid acne products. This requirement applies to the branded products listed in the policy (examples include Clindagel 1% topical gel, Amzeeq 4% topical foam, Acanya 1.2%/2.5% gel, BenzaClin 1%/5% gel, Neuac Kit, Onexton 1.2%/3.75% gel, and other clindamycin/benzoyl peroxide formulations) and must be obtained before coverage will be provided.

    • Prior authorization applies when coverage is available and medical necessity criteria are met.
    • Receipt of sample product does not satisfy criteria or substitute for prior authorization.
    Step Therapy

    Follow step‑therapy trials (trial and failure/intolerance to specified alternatives)

    Step therapy is enforced: most branded products require documented trial and failure, intolerance, or contraindication to specified alternative topical agents before the branded product is covered. Required alternatives vary by product (for example, trials of bioequivalent generic clindamycin gel, topical dapsone 5% gel, topical erythromycin products, or benzoyl peroxide combinations as specified in each product’s criteria).

    Definitions and Product Summaries

    Sulfacetamide/sulfur products — indication and mechanism
    IndicationTreatment of acne vulgaris; also used for acne rosacea and seborrheic dermatitis
    Sulfacetamide actionAntimicrobial
    Sulfur actionAntimicrobial and keratolytic (causes peeling and drying effect)
    Common formulation noteSulfacetamide sodium and sulfur are used together in topical products; refer to product labeling for specific details

    Background

    Topical non‑retinoid agents include antibiotics and antimicrobial combinations such as clindamycin, topical minocycline foam, and benzoyl peroxide combinations, as well as sulfacetamide/sulfur formulations. These products are primarily indicated for acne vulgaris, and some combinations are also used for conditions such as rosacea and seborrheic dermatitis. Formulation choice (e.g., gel, foam, cream, lotion) is often guided by skin type and tolerability; clinicians commonly combine topical agents (for example, a retinoid with benzoyl peroxide) to enhance efficacy while minimizing resistance concerns associated with topical antibiotics.

    Revision History and Policy Changes

    2026-08-15reviewLatest

    No criteria changes noted; policy effective date updated to 08/15/2026.

    2026-07-30review

    No criteria changes noted during review on 07/30/2026.

    2025-09-01revision
    Policy Summary
    PayerCigna
    PolicyTopical Acne-Non-Retinoid Products
    Policy CodePolicy IP0166
    Change TypeRemoved dapsone criteriapreference table revised
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review Date
    Key ActionObtain prior authorization and document required prior trials, contraindications, or intolerance per product-specific criteria before coverage will be approved.
    SourceLink
    On This Page
    Coverage Criteria for Topical Non‑Retinoid Acne ProductsProvider Actions, Prior Authorization and Documentation RequirementsDefinitions and Product SummariesBackgroundRevision History and Policy Changes
    1 of 2

    Employer plan wording.

    Neuac Kit medical necessity: Documentation of failure, contraindication, or intolerance to ALL of the following: 1) Neuac gel; 2) topical benzoyl peroxide (4% or 8% gel) with topical clindamycin (1% gel) used concurrently; 3) benzoyl peroxide/erythromycin (5%/3%) gel.all

    Employer plan wording.

    • Amzeeq — failure, contraindication, or intolerance to BOTH: one topical clindamycin-containing product AND one topical erythromycin-containing product.
    • Acanya/BenzaClin/Onexton/Neuac — trials of specified bioequivalent generic clindamycin/benzoyl peroxide gels or concurrent benzoyl peroxide with topical clindamycin and other listed alternatives as detailed per product criteria.
    Documentation Required

    Provide detailed clinical documentation of prior trials, contraindications, or intolerance

    Document the specific prior trials, contraindications, or intolerances required by the product‑specific criteria to support authorization and continuation. Continuation (reauthorization) also requires documentation of beneficial response. Note that receipt of a sample does not satisfy trial requirements.

    • Include dates, product names, doses/formulations, duration of each prior trial, and clinical reason for discontinuation (failure, intolerance, or contraindication).
    • For products requiring a trial of a bioequivalent generic, document inability to take the generic due to a formulation difference in inactive ingredients that would cause a significant allergy or serious adverse reaction.
    • For reauthorization, provide documentation of beneficial response to the covered product.
    Billing Rule

    Submit claims with appropriate covered diagnosis/procedure codes or risk denial

    Use the appropriate covered diagnosis and procedure codes when submitting claims; claims submitted without covered code(s) under this Coverage Policy will be denied as not covered. When billing, providers must use the most appropriate codes as of the submission date.

    • Claims lacking covered diagnosis or procedure codes under this policy will be denied as not covered.
    • Ensure dosage, frequency, duration, and site of care are reasonable and supported by documentation when submitting requests.

    Employer Preferred Product table: removed Onexton preferred product requirements (listed 07/02/2025; effective 09/01/2025).

    2025-01-01removal

    Removed Dapsone products (Aczone) medical necessity criteria from this policy (listed 09/19/2024; effective 01/01/2025).